Ignite Creation Date:
2025-12-24 @ 7:06 PM
Ignite Modification Date:
2026-02-25 @ 11:05 PM
Study NCT ID:
NCT03066557
Status:
UNKNOWN
Last Update Posted:
2017-02-28
First Post:
2017-02-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C553458', 'term': 'apatinib'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 80}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2017-03-15', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-02', 'completionDateStruct': {'date': '2018-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-02-23', 'studyFirstSubmitDate': '2017-02-20', 'studyFirstSubmitQcDate': '2017-02-23', 'lastUpdatePostDateStruct': {'date': '2017-02-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-02-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2018-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'PFS', 'timeFrame': '2 years', 'description': 'progression free survival'}], 'secondaryOutcomes': [{'measure': 'TTP', 'timeFrame': '2 years', 'description': 'Time To Progress'}, {'measure': 'OS', 'timeFrame': '2 years', 'description': 'Overall Survival'}, {'measure': 'DCR', 'timeFrame': '2 years', 'description': 'Disease Control Rate'}, {'measure': 'ORR', 'timeFrame': '2 years', 'description': 'Objective Response Rate'}, {'measure': 'QoL', 'timeFrame': '2 years', 'description': 'Quality of Life'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Hepatocellular Carcinoma', 'Apatinib'], 'conditions': ['Hepatocellular Carcinoma']}, 'descriptionModule': {'briefSummary': 'Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC. Currently, Sorafenib is the only choice approved by FDA for advanced HCC, although it prolongs the survival for less than 3 months. The treatment of advanced HCC still has a long way to go.\n\nAt present, the relevant phase II and phase III clinical studies of apatinib on advanced HCC are ongoing. Based on our important discovery of previous clinical studies, we intend to enlarge the sample size and make further observation for the efficacy and safety of apatinib in patients with advanced HCC.', 'detailedDescription': 'Hepatocellular carcinoma (HCC) is one of the lethal human cancers worldwide and its incidence matches mortality, reflecting the poor prognosis of this disease. The surgical resection rate of HCC is low, and the prognosis is poor. Although transarterial chemoembolization (TACE) is the main treatment for HCC patients who are not candidates for surgical resection, it is not considered a curative procedure. For HCC, poor TACE efficacy or TACE failure may be related to tumor angiogenesis of the residual disease. Among the many regulatory factors in tumor angiogenesis, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) play vital roles in this process.\n\nSorafenib is the first systemic treatment drug, which has been approved by the FDA for advanced HCC. In order to find an new VEGFR-inhibitor with better effect and lower toxicity, Jiangsu Hengrui Medicine Co., Ltd. developed Apatinib, a high-performance VEGFR-2 tyrosine kinase inhibitor. Apatinib plays anti angiogenic effect in the treatment of malignant tumor mainly through inhibition of VEGFR-2, in vivo and in vitro experiments showed good tumor growth inhibitory activity on Hepatocellular carcinoma, this study aims to further verify the efficacy and safety of Apatinib for hepatocellular carcinoma patients who are not candidates for curative surgery, the primary endpoint is Progression Free Survival (PFS).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Aged 18 - 75 years old;\n2. Must be strictly in accordance with the "guidelines for primary liver cancer diagnosis and treatment" (2011 edition). According to clinical diagnosis standard or confirmed by histopathology or cytology, the patients with advanced primary liver cancer who can\'t be?removed surgically, and can\'t accept palliative surgery or radiation therapy, and have at least one measurable lesions;The biggest tumor 10 cm or less;\n3. Refuse the treatment of sorafenib;\n4. The Child - Pugh( liver function grade): grade A or better grade of B (≤7 points);\n5. BCLC stage for B or C;\n6. Within 1 week before into the study,ECOG PS0-1;\n7. The expected lifetime of patients should be equal to or more than 12 weeks;\n8. The main viscera function of patients must be normal, and should meet the following requirements:\n\n * Blood routine examination must meet: HB≥90 g/L, ANC≥1.5×10\\^9/L, PLT≥60×10\\^9/L;\n * Biochemical examination should meet the following criteria: ALB ≥29 g/L, ALT and AST\\<5xULN, TBIL ≤1.5xULN, creatinine≤1.5xULN (Only one of albumin and bilirubin can be 2 points in the rating of Child-Pugh);\n9. The patients are willing to join in this study, and have signed the informed consent. The patients have good adherence, and are willing to cooperate with the follow-up.\n\nExclusion Criteria:\n\n1. Patients have received radiotherapy or chemotherapy within four weeks before the study;\n2. In the past (within 5 years) or at the same time,patients were diagnosed with other malignant tumor which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in situ,they can be excepted;\n3. Patients who are diagnosed with hypertension which cant be reduced to normal range via antihypertensive drug treatment(systolic blood pressure\\> 140 mmHg / diastolic blood pressure\\> 90 mmHg);\n4. Patients who are diagnosed with II or higher level of myocardial ischemia, myocardial infarction, uncontrolled arrhythmia(including QTc interval prolongation men\\> 450 ms, female\\> 470 ms);\n5. There are many factors which can influence the oral drug absorption (such as unable to swallow, chronic diarrhea and intestinal obstruction, which can significantly affect the drug taking and absorption);\n6. Within 6 months in the past,the patients have a history of gastrointestinal bleeding or a gastrointestinal bleeding tendency, for example,there is a risk of bleeding of esophageal varicose veins, local active ulcerative lesions, defecate occult blood ≥ (+ +)(+) shall not be admitted into the study;\n7. within 28 days before being admitted into the study, there is abdominal fistula, gastrointestinal perforation or abdominal abscess;\n8. Blood coagulation function is abnormal (INR\\>1.5 or PT\\> ULN+4s), and the patients are able to be faced with a bleeding tendency or being treated with thrombolysis and anticoagulation;\n9. Has been diagnosed with ?the central nervous system metastases or the brain metastases has been known;\n10. There are past medical history or history of present illness of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug related pneumonia,pulmonary function test suggests there is objective evidence of severely damaged lung function;\n11. Urine routine inspection suggests that the urine protein ≥++;24 hours urine protein examination\\>1.0 g;\n12. Within 7 days before being admitted into the study,patients have received a potent CYP3A4 inhibitor treatment, or within 12 days before being admitted into the study,patients have received potent CYP3A4 inducers treatment;\n13. Pregnant or lactating women;Patients with fertility are unwilling or unable to take effective contraceptive measures;\n14. With a mental illness, or has a history of psychiatric drugs abuse;\n15. Patients with HIV infection.'}, 'identificationModule': {'nctId': 'NCT03066557', 'briefTitle': 'Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'Jiangsu Cancer Institute & Hospital'}, 'officialTitle': 'Study of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Apatinib in Patients With Hepatocellular Carcinoma Trial', 'orgStudyIdInfo': {'id': 'ANIMATE-JS-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'study group', 'description': 'TACE and Apatinib', 'interventionNames': ['Procedure: TACE and Apatinib']}, {'type': 'EXPERIMENTAL', 'label': 'control group', 'description': 'TACE alone', 'interventionNames': ['Procedure: TACE']}], 'interventions': [{'name': 'TACE and Apatinib', 'type': 'PROCEDURE', 'otherNames': ['Aitan'], 'description': 'TACE and Apatinib 250mg po qd', 'armGroupLabels': ['study group']}, {'name': 'TACE', 'type': 'PROCEDURE', 'description': 'TACE', 'armGroupLabels': ['control group']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Chen Shixi, Bachelor', 'role': 'CONTACT', 'email': 'chenshixi2007@126.com', 'phone': '+86-13505192984'}, {'name': 'Yin Guowen', 'role': 'CONTACT', 'email': 'jsnjygw@163.com', 'phone': '+86-13951841177'}], 'overallOfficials': [{'name': 'Feng Jifeng, Doctor', 'role': 'STUDY_CHAIR', 'affiliation': 'Jiangsu Cancer Institute & Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Within six months after the trial complete'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Jiangsu Cancer Institute & Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Jiangsu HengRui Medicine Co., Ltd.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'director of department', 'investigatorFullName': 'Shixi Chen', 'investigatorAffiliation': 'Jiangsu Cancer Institute & Hospital'}}}}